Universal Biosensors, Inc. (UBI.AX)
- Previous Close
0.1650 - Open
0.1700 - Bid 0.1600 x 8261800
- Ask 0.1650 x 5792900
- Day's Range
0.1650 - 0.1700 - 52 Week Range
0.1350 - 0.3200 - Volume
12,362 - Avg. Volume
610,392 - Market Cap (intraday)
38.181M - Beta (5Y Monthly) 0.94
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date Mar 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices used in healthcare (point-of-care), wine, food, and agriculture industries in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of the anticoagulant therapy warfarin; and Sentia wine testing products, such as free SO2, malic acid, glucose, fructose, total acid, and titratable acidity. It also offers non-diagnostic laboratory services and performs coagulation testing services. The company has a license agreement with LifeScan Global Corporation to develop a test strip and a meter to be used for the detection and monitoring of diabetes in non-humans. Universal Biosensors, Inc. was incorporated in 2001 and is based in Rowville, Australia.
www.universalbiosensors.comRecent News: UBI.AX
Performance Overview: UBI.AX
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: UBI.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: UBI.AX
Valuation Measures
Market Cap
38.18M
Enterprise Value
32.91M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.28
Price/Book (mrq)
1.96
Enterprise Value/Revenue
4.96
Enterprise Value/EBITDA
-5.72
Financial Highlights
Profitability and Income Statement
Profit Margin
-101.64%
Return on Assets (ttm)
-27.39%
Return on Equity (ttm)
-29.57%
Revenue (ttm)
6.63M
Net Income Avi to Common (ttm)
-6.74M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
10.24M
Total Debt/Equity (mrq)
25.49%
Levered Free Cash Flow (ttm)
-19.86M